Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 18;157(5):1789–1798. doi: 10.1210/en.2015-1965

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article has been published under the terms of the Creative Commons Attribution License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).

PMC Copyright notice

Figure 4. — Pituitary NET imaging and volumetric measurements. A, Cranial MRI with gadolinium enhancement demonstrating pituitary NETs (outlined in red dotted line) in a PBS-treated (upper panels) Men1^+/− mouse and a pasireotide-treated (lower panels) Men1^+/− mouse at age 12 and 21 mo. B, MRI was used to assess pituitary NET volumes, pretreatment (12 mo) and 9 mo post-treatment (21 mo). The PBS-treated Men1^+/− mice (n = 32) and pasireotide-treated Men1^+/− mice (n = 32) had similarly sized pituitary NETs of approximately 0.3–3.0 mm³ at age 12 mo (baseline). However by age 21 mo, 10 of 32 of PBS-treated Men1^+/− mice (31%) had developed large pituitary NETs of at least 10 mm³, whereas only two of 32 of Men1^+/− mice (6.3%) treated with pasireotide had developed pituitary NETs with volumes at least 10 mm³. There was no evidence of pituitary NET development in the remaining 15 of 47 PBS-treated Men1^+/− mice (31.9%) or 19 of pasireotide-treated Men1^+/− mice 51 (37.3%) at age 21 mo, consistent with our previous observation that pituitary NETs only develop in a subset of female Men1^+/− mice (29). C, The mean pituitary NET volumes at 12 mo in the PBS-treated (open bars) (n = 32) and pasireotide-treated (filled bars) (n = 32) Men1^+/− mice were not significantly different (mean volume ± SEM of PBS-treated, 0.844 ± 0.066 mm³ vs pasireotide-treated, 0.803 ± 0.058 mm³). However, after 9 mo of treatment, at the age of 21 mo, the pasireotide-treated mice (n = 32) had a significantly smaller increase in pituitary NET volume when compared with the PBS-treated Men1^+/− mice, such that the mean ± SEM pituitary tumor volume of the pasireotide-treated Men1^+/− mice was 2.872 ± 0.728 mm³ compared with 8.847 ± 1.948 mm³ of the PBS-treated Men1^+/− mice (**, P < .01). Error bars represent SEM.